GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (HKSE:09995) » Definitions » Equity-to-Asset

RemeGen Co (HKSE:09995) Equity-to-Asset : 0.46 (As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is RemeGen Co Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. RemeGen Co's Total Stockholders Equity for the quarter that ended in Jun. 2024 was HK$2,869 Mil. RemeGen Co's Total Assets for the quarter that ended in Jun. 2024 was HK$6,195 Mil. Therefore, RemeGen Co's Equity to Asset Ratio for the quarter that ended in Jun. 2024 was 0.46.

The historical rank and industry rank for RemeGen Co's Equity-to-Asset or its related term are showing as below:

HKSE:09995' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.94   Med: 0.74   Max: 0.89
Current: 0.46

During the past 6 years, the highest Equity to Asset Ratio of RemeGen Co was 0.89. The lowest was -0.94. And the median was 0.74.

HKSE:09995's Equity-to-Asset is ranked worse than
67.79% of 1509 companies
in the Biotechnology industry
Industry Median: 0.67 vs HKSE:09995: 0.46

RemeGen Co Equity-to-Asset Historical Data

The historical data trend for RemeGen Co's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co Equity-to-Asset Chart

RemeGen Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial -0.34 0.87 0.83 0.83 0.62

RemeGen Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.89 0.83 0.74 0.62 0.46

Competitive Comparison of RemeGen Co's Equity-to-Asset

For the Biotechnology subindustry, RemeGen Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RemeGen Co's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RemeGen Co's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where RemeGen Co's Equity-to-Asset falls into.



RemeGen Co Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

RemeGen Co's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=3759.612/6046.675
=0.62

RemeGen Co's Equity to Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

Equity to Asset (Q: Jun. 2024 )=Total Stockholders Equity/Total Assets
=2868.569/6195.009
=0.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


RemeGen Co  (HKSE:09995) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


RemeGen Co Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of RemeGen Co's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


RemeGen Co Business Description

Traded in Other Exchanges
Address
58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of innovative biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat major diseases such as autoimmune diseases, oncology, and ophthalmology. The company has its operations in China and the USA and derives the majority of its revenue from China.
Executives
Fang Jianmin 2103 Interests held jointly with another person
Lin Jian 2103 Interests held jointly with another person
Wang Weidong 2201 Interest of corporation controlled by you
Wang Liqiang 2103 Interests held jointly with another person
Yi Fang Da Ji Jin Guan Li You Xian Gong Si 2102 Investment manager
Rongchang Holding Group Ltd. 2103 Interests held jointly with another person
Yantai Rongda Venture Capital Center (limited Partnership) 2103 Interests held jointly with another person
Yang Minhua 2103 Interests held jointly with another person
Xiong Xiaobin 2103 Interests held jointly with another person
Wen Qingkai 2103 Interests held jointly with another person
Wei Jianliang 2103 Interests held jointly with another person
Wang Xudong 2103 Interests held jointly with another person
I-nova Limited 2101 Beneficial owner
Deng Yong 2103 Interests held jointly with another person
Morgan Stanley 2201 Interest of corporation controlled by you

RemeGen Co Headlines

No Headlines